Form 4: VolitionRx Executive Receives Stock Award in Lieu of Cash Compensation

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, received 13,143 restricted stock units in lieu of cash compensation.

Summary

• Ann-Louise Batchelor, the Group Chief Marketing Officer of VolitionRx, was granted 13,143 restricted stock units (RSUs) on December 1, 2024.
• These RSUs were awarded in place of cash compensation that was due to her.
• The RSUs vest in three equal installments of 4,381 units on December 1, 2024, January 1, 2025, and February 1, 2025.
• A final vesting of all remaining units is scheduled for July 1, 2025.
• The vesting is contingent on continued service with the company through each vesting date.
• Upon vesting, Batchelor will receive common stock equal to the number of vested RSUs.
• Following this transaction, Batchelor directly owns 114,709 common shares and indirectly owns 29,406 shares through her spouse.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally neutral to positive. The use of RSUs is a common practice and does not indicate any significant positive or negative sentiment.

Positives

• The use of RSUs in lieu of cash compensation can help preserve the company's cash reserves.
• The vesting schedule of the RSUs aligns the executive's interests with the long-term performance of the company.

Risks

• The value of the RSUs is subject to the volatility of the company's stock price.
• The executive must remain employed with the company through the vesting dates to receive the full benefit of the RSUs.

Future Outlook

The executive will receive shares of common stock upon the vesting of the RSUs, subject to continued service.

Industry Context

The use of stock-based compensation is a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock-based compensation is a standard practice across the biotechnology industry, with companies like Exact Sciences (EXAS) and Guardant Health (GH) also utilizing similar methods to incentivize executives.
• The vesting schedule of the RSUs is typical, with staggered vesting periods to ensure continued service and commitment from the executive.
• The amount of RSUs granted is likely based on the executive's role and performance, which is consistent with industry norms.

Stakeholder Impact

• Shareholders may view the stock award as a positive sign of aligning executive interests with company performance.
• Employees may see this as a standard practice for executive compensation.

Next Steps

• The executive will continue to vest in the RSUs over the next several months, contingent on continued service.
• The executive will receive shares of common stock upon the vesting of the RSUs.

Key Dates

Keywords

restricted stock units, RSUs, stock compensation, executive compensation, insider trading, Form 4, VolitionRx, VNRX